GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of genuine question about API source that I am slightly embarrassed to ask — 68 comments in the full submission. View in context.
1.1k
c/compounding·submitted 5 months ago by u/niels_roos

genuine question about API source that I am slightly embarrassed to ask

Explainerbranch of 8 comments

Question in the title, detail here: genuine question about API source that I am slightly embarrassed to ask. Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history. Concentration on the compounded vial was different from what I had been…

Read the full submission and all 68 comments →

This branch

8 comments, started 5 months ago
u/camila_sandvik95 points·5 months ago

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

replysharereportpermalink
u/niels_roosOP72 points·5 months ago

the API source is the question nobody asks and everybody should

replysharereportpermalink
u/enzo_ferrari53 points·5 months ago

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

replysharereportpermalink
u/niels_roosOP20 points·5 months ago

Who is the prescriber, and are they the same organisation as the pharmacy?

replysharereportpermalink
u/formulary_fighterappeals78 points·5 months ago

salt forms are the recurring argument and the answer is boring

replysharereportpermalink
u/elin_ferrari53 points·5 months ago

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

replysharereportpermalink
u/camila_sandvik74 points·4 months ago

503A is patient-specific, 503B is outsourcing facility, they are not the same thing

replysharereportpermalink
u/kian_ferreira50 points·4 months ago

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

replysharereportpermalink

← back to the whole thread

About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/compounding
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/formulary_fighteru/usp_appendixu/quiet_moderatoru/prior_auth_pain
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →